Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 241 participants.
Also called NCT01084005
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 241 participants
- Registry
-
NCT01084005 -
2009-015255-25
-
- Other papers using this trial's data
- Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Results first posted
- Countries
- Australia, Canada, Denmark, Netherlands, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT01084005. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2011-06 (actual). Results posted on 2012-07-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- linagliptin
- Intervention (Drug)
- placebo
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01084005- Content hash
b38f78012ee4dddfbab122ecf43c7575811a1404fce7bc8dcad3dded0914e206